Nuvation Bio Inc.
NYSE:NUVBBiotechnology
+$0.06 today
- Market cap
- $1.33B
- Beta
- 1.56
- P/E (TTM)
- -12.8
- EPS (TTM)
- -$0.42
Volume 5.96M
Average 4.07M
NUVB Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Nuvation Bio Inc.NYSE: NUVB
Capital Expenditures · Q2 FY2026 · quarter ended Jun 2026
Capital expenditures turns positive
Q2 FY2026 capital expenditures was $48K, compared with -$181K a year earlier. Trailing-twelve-month capital expenditures was -$101K. Over 3 fiscal years it compounded at -1.5% a year.
Context
- Capital expenditures amounted to 0.6% of revenue in FY2025, down 1.5 pp from a year earlier.
- Capital expenditures grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly capital expenditures holds near $48K or moves back toward the trailing-twelve-month quarterly average of -$25.25K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (354K) USD
- Year-over-year change
- -118.5%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (354K) | -118.5% |
| FY2024 | 2024-12-31 | (162K) | -134.8% |
| FY2023 | 2023-12-31 | (69K) | +81.4% |
| FY2022 | 2022-12-31 | (370K) | -31.2% |
| FY2021 | 2021-12-31 | (282K) | — |
Capital Expenditures vs competitors
How NUVB compares with its peers on the latest reported figures
- NUVB's LTM Jun 2026 capital expenditures of $101K is the 10th largest of the 11 companies compared; the peer median is $1.32M.
- Its year-over-year change of -74.0% is the 10th highest of 11, against a peer median of +22.6%.
- Capital expenditures amounts to 0.1% of revenue for NUVB, versus a peer median of 4.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $17.42M | -64.1% | -16.2% | 25.7% | |
| LTM Mar 2026 | $14.74M | +396.9% | +47.9% | 28.3% | |
| LTM Sep 2026 | $7.48M | +241.6% | +14.1% | 6676.8% | |
| LTM Jun 2026 | $5.39M | +332.5% | +185.7% | — | |
| LTM Jun 2026 | $1.7M | +217.0% | -14.7% | 2.4% | |
| LTM Mar 2026 | $945K | +77.3% | -45.5% | 4.4% | |
| LTM Jun 2026 | $408K | -68.1% | +116.6% | — | |
| LTM Jun 2026 | $173.59K | -32.2% | -4.8% | 0.1% | |
| LTM Sep 2026 | $126K | -72.4% | -64.1% | — | |
| LTM Jun 2026 | $101K | -74.0% | -1.5% | 0.1% | |
| LTM Mar 2026 | $14K | -99.9% | -70.8% | 0.1% | |
| Peer median (excluding NUVB) | $1.32M | +22.6% | -9.7% | 4.4% | |
Competitors are the stored peer set for NUVB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (86.85M) | (104.2M) | (75.8M) | (567.94M) | (204.63M) |
| Depreciation & Amortization | 184K | 199K | 222K | 683K | 1.74M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 9.27M | 16.29M | 19.51M | 32.28M | 35.89M |
| Change in Working Capital | 4.79M | (3.45M) | 540K | (12.51M) | (11.98M) |
| Accounts Receivables | (1.95M) | 554K | (1.22M) | (12.59M) | (3.07M) |
| Inventory | 0 | 0 | 0 | 0 | (11.41M) |
| Accounts Payables | 1.86M | (1.79M) | 70K | (1.65M) | 3.13M |
| Other Working Capital | 4.88M | (2.22M) | 1.69M | 1.74M | (630K) |
| Other Non-Cash Items | 4.41M | (4.95M) | (12.47M) | 417.08M | 5.55M |
| Operating Cash Flow | (68.19M) | (96.11M) | (68M) | (130.41M) | (173.43M) |
| Capital Expenditures | (282K) | (370K) | (69K) | (162K) | (354K) |
| Acquisitions (Net) | 0 | 0 | 0 | 12.43M | 0 |
| Purchases of Investments | (609.3M) | (520.31M) | (703.37M) | (339.65M) | (354.42M) |
| Sales of Investments | 154.91M | 584.12M | 712.35M | 450.08M | 462.29M |
| Other Investing Activities | 0 | 13K | 14K | 0 | 0 |
| Investing Cash Flow | (454.67M) | 63.46M | 8.92M | 122.7M | 99.52M |
| Debt Repayment | 0 | 0 | 0 | (4.55M) | 191.11M |
| Common Stock Issued | 0 | 0 | 0 | 4.89M | 11.42M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 625.53M | 1.33M | 628K | 0 | 0 |
| Financing Cash Flow | 625.53M | 1.33M | 628K | 331K | 202.54M |
| Effect of Forex Changes | 0 | 0 | 0 | 453K | (265K) |
| Net Change in Cash | 102.67M | (31.32M) | (58.45M) | (6.93M) | 128.36M |
| Free Cash Flow | (68.47M) | (96.48M) | (68.07M) | (130.58M) | (173.78M) |
Nuvation Bio Inc.
NYSE:NUVB
Intrinsic Alpha fair value
Locked
Current Price
$3.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.